Phase I, multi-centre, randomised, placebo-controlled, dose escalation study to assess local and systemic tolerability of therapeutic DNA plasmid pdpSC18 vaccine administered by Particle Mediated Epidermal Delivery using PowderJect ND10 delivery system in subjects with chronic hepatitis B infection

Trial Profile

Phase I, multi-centre, randomised, placebo-controlled, dose escalation study to assess local and systemic tolerability of therapeutic DNA plasmid pdpSC18 vaccine administered by Particle Mediated Epidermal Delivery using PowderJect ND10 delivery system in subjects with chronic hepatitis B infection

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2008

At a glance

  • Drugs Hepatitis B DNA vaccine (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Nov 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
    • 20 Nov 2008 Actual trial completion date identified as December 2007 from ClinicalTrials.gov.
    • 04 Apr 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top